7-氯-8-甲基-2-苯基喹啉-4-羧酸 | 500346-26-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 7-氯-8-甲基-2-苯基喹啉-4-羧酸
• 英文名称: 7-chloro-8-methyl-2- phenylquinoline-4-carboxylic acid
• 英文别名: 7-chloro-8-methyl-2-phenylquinoline-4-carboxylic acid；Y-0452；7-chloro-8-methyl-2-phenyl-quinoline-4-carboxylic acid；7-Chlor-8-methyl-2-phenyl-chinolin-4-carbonsaeure
• CAS: 500346-26-9
• 化学式: C₁₇H₁₂ClNO₂
• mdl: MFCD03422093
• 分子量: 297.741
• InChiKey: ZVEMFXOLQBHHKA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-氯-8-甲基-2-苯基喹啉-4-羧酸 在 氯化亚砜 、 二氯甲烷 、 aluminum isopropoxide 、 异丙醇 作用下， 生成 2-bromo-1-(7-chloro-8-methyl-2-phenyl-[4]quinolyl)-ethanol
  参考文献：
  名称：

  抗疟药；7-氯-4-羟基-和4,7-二氯-1-甲基甲硫基。

  摘要：

  DOI：

  10.1021/ja01213a041
• 作为产物：
  描述：

  苯甲醛 、 3-氯-2-甲基苯胺 、 丙酮酸 在 乙醇 作用下， 生成 7-氯-8-甲基-2-苯基喹啉-4-羧酸
  参考文献：
  名称：

  抗疟药；7-氯-4-羟基-和4,7-二氯-1-甲基甲硫基。

  摘要：

  DOI：

  10.1021/ja01213a041

文献信息

• Phenylquinoline compositions for treatment of ocular disorders and conditions
  申请人：The Board of Regents of the University of Oklahoma

  公开号：US11337968B2

  公开（公告）日：2022-05-24

  Compositions containing a phenylquinoline derivative compound having peroxisome proliferator-activated receptor a (PPARα) agonistic activity, and methods of their use in enhancing PPARα activity in retinal cells, and in treating ocular disorders or conditions, such as but not limited to retinal inflammation, retinal neovascularization, retinal vascular leakage, retinopathy of prematurity, diabetic retinopathy, age-related macular degeneration, and diabetic macular edema are disclosed.

  本发明公开了含有具有过氧化物酶体增殖激活受体 a（PPARα）激动活性的苯基喹啉衍生物化合物的组合物，以及将其用于增强视网膜细胞中 PPARα 活性和治疗眼部疾病或病症的方法，例如但不限于视网膜炎症、视网膜新生血管、视网膜血管渗漏、早产儿视网膜病变、糖尿病视网膜病变、老年性黄斑变性和糖尿病黄斑水肿。
• Agonists of peroxisome proliferator-activated receptor alpha and methods of use
  申请人：The Board of Regents of the University of Oklahoma

  公开号：US11447452B2

  公开（公告）日：2022-09-20

  Benzyl derivative compounds having peroxisome proliferator-activated receptor α (PPARα) agonistic activity, compositions containing such compounds, and methods of their use in enhancing PPARα activity for treating diseases and/or conditions involving inflammation and/or angiogenesis, particularly ocular diseases and/or conditions such as but not limited to retinal inflammation, retinal neovascularization, retinal vascular leakage, retinopathy of prematurity, diabetic retinopathy, age-related macular degeneration, and diabetic macular edema are disclosed.

  本发明公开了具有过氧化物酶体增殖激活受体α（PPARα）激动活性的苄基衍生物化合物、含有此类化合物的组合物，以及将其用于增强 PPARα 活性以治疗涉及炎症和/或血管生成的疾病和/或病症的方法，特别是眼部疾病和/或病症，如但不限于视网膜炎症、视网膜新生血管、视网膜血管渗漏、早产儿视网膜病变、糖尿病视网膜病变、老年性黄斑变性和糖尿病黄斑水肿。
• AGONISTS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA AND METHODS OF USE
  申请人：The Board of Regents of the University of Oklahoma

  公开号：EP3765450A1

  公开（公告）日：2021-01-20
• METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1
  申请人：PHUSIS THERAPEUTICS, INC.

  公开号：US20150307482A1

  公开（公告）日：2015-10-29

  Embodiments include compositions and methods of inhibiting CNKSR1 and methods of identifying inhibitors of CNKSR1.
• PHENYLQUINOLINE COMPOSITIONS FOR TREATMENT OF OCULAR DISORDERS AND CONDITIONS
  申请人：The Board of Regents of the University of Oklahoma

  公开号：US20190336491A1

  公开（公告）日：2019-11-07

  Compositions containing a phenylquinoline derivative compound having peroxisome proliferator-activated receptor a (PPARα) agonistic activity, and methods of their use in enhancing PPARα activity in retinal cells, and in treating ocular disorders or conditions, such as but not limited to retinal inflammation, retinal neovascularization, retinal vascular leakage, retinopathy of prematurity, diabetic retinopathy, age-related macular degeneration, and diabetic macular edema are disclosed.